RLH Capital’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

RLH Capital’s Portfolio DMAAR Stock Details DMAAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24.1K	Buy	+399,391	New	+$42.3K	0.01%	97

Other funds holding DMAAR

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return

Hudson Bay Capital Management

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Toronto Dominion Bank

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

RLH Capital's DMAAR Position: Q1 2026 in Review

RLH Capital opened a new position in Drugs Made In America Acquisition Corp Rights (DMAAR) in Q1 2026: 399,391 shares worth $24.1K. The stake represents 0.01% of the portfolio and ranks #97 among its holdings.

35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

RLH Capital held 399,391 shares of Drugs Made In America Acquisition Corp Rights worth $24.1K as of Q1 2026.
Drugs Made In America Acquisition Corp Rights was a new RLH Capital position in Q1 2026.
Drugs Made In America Acquisition Corp Rights made up 0.01% of RLH Capital's portfolio in Q1 2026, its #97 holding.
35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on RLH Capital's 13F filing for Q1 2026, filed 29 Apr 2026.